Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-101/GI-101A Alone or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453Phase 2Recruiting
- Sponsor
- GI Innovation
- Start
- Aug 2021
- Primary completion
- Jun 2028
- Modality
- Antibody Fragments, Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label trial of GI-101 in solid tumor, Cervical Cancer (CC), urothelial carcinoma (UC) and 2 more (5 arms), sponsored by GI Innovation. Primary endpoints: Dose-Limiting Toxicity at 24 months, Adverse Events and Immune-related Adverse Events at 24 months and 3 more. Started Aug 2021; status: recruiting.
02
Drugs
GI-101
03
Conditions
solid tumorCervical Cancer (CC)urothelial carcinoma (UC)clear cell renal cell carcinoma (ccRCC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04977453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977453.